Galderma enters fierce European atopic dermatitis market with Nemluvio approval
Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of ...
Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...
Cure Today25 天
The Significance of the Subcutaneous Opdivo FDA Approval in Solid Tumors
The Dec. 27, 2024, Food and Drug Administration (FDA) approval of the subcutaneous injection formulation of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for patients with solid tumors opened up ...
Cure Today1 个月
The Subcutaneous Approval of Opdivo Makes Waves in Future of Cancer Care
Most recently, the Food and Drug Administration (FDA) approved treatment with the subcutaneous injection formulation of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for patients with solid tumors ...
pharmaphorum4 天
Opdivo's subcutaneous PD-1 inhibitor cleared in US
Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.
Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis ...
Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% ...